Craig Michael Horbinski

  • 4132 Citations
20002024
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

The main focus of our laboratory is developing a better understanding of how key mutations in gliomas alter their biological characteristics, and how best to exploit specific weaknesses that such mutations often impart. In particular, our laboratory focuses on mutant isocitrate dehydrogenase 1 (mutIDH1), which is present in the vast majority of WHO grade II and III gliomas. This mutation has profound effects on the epigenome and metabolome, yet produces tumors that are markedly less aggressive. Our work indicates that mutIDH1 also dramatically alters the glioma’s micro-environmental landscape by preventing the thrombosis-necrosis phenomenon that is characteristic of IDH1 wild-type gliomas. Furthermore, mutIDH1 increases the risk of seizures in patients. We are currently exploring the mechanisms by which these phenomena occur, as it will have major implications for understanding why mutIDH1 gliomas are less aggressive and how to better manage both wtIDH1 and mutIDH1 gliomas. On a clinical level, I specialize in the use of molecular testing in brain tumors to improve our diagnostic and prognostic accuracy. This is helping us achieve the goal of personalized medicine through cutting-edge next generation sequencing.

Training Experience

2004Postdoctoral Fellowship, University of Pittsburgh
2007Residency, University of Pittsburgh
2009Fellowship, University of Pittsburgh

Education/Academic qualification

MD, State University of New York

… → 2003

PhD, State University of New York

… → 2003

Research interests

  • Brain Cancer / Nervous System Cancer
  • Cancer Biology
  • Molecular Diagnostics
  • Pathology

Fingerprint Dive into the research topics where Craig Michael Horbinski is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 13 Similar Profiles
Glioma Medicine & Life Sciences
Glioblastoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Isocitrate Dehydrogenase Medicine & Life Sciences
Mutation Medicine & Life Sciences
Brain Neoplasms Medicine & Life Sciences
Meningioma Medicine & Life Sciences
Pediatrics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2015 2024

Receptor Protein-Tyrosine Kinases
Thromboplastin
Glioblastoma
Neoplasms
Brain Neoplasms
Antigen Receptors
Glioblastoma
Cell- and Tissue-Based Therapy
T-Cell Antigen Receptor
Glioma
Glioblastoma
Brain Neoplasms
Therapeutics
Neoplasms
Survival

Research Output 2000 2019

1 Citation (Scopus)

Advances in multidisciplinary therapy for meningiomas

International Consortium on Meningiomas, Jan 14 2019, In : Neuro-oncology. 21, p. I18-I31

Research output: Contribution to journalArticle

Open Access
Meningioma
trabectedin
Therapeutics
Radiotherapy
Focal Adhesion Protein-Tyrosine Kinases

Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma (Nature Medicine, (2019), 25, 3, (462-469), 10.1038/s41591-019-0349-y)

Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., Filip, I., Orenbuch, R., Goetz, M., Yamaguchi, J. T., Cloney, M., Horbinski, C. M., Lukas, R. V., Raizer, J., Rae, A. I., Yuan, J. & 7 others, Canoll, P., Bruce, J. N., Saenger, Y. M., Sims, P., Iwamoto, F. M., Sonabend Worthalter, A. M. & Rabadan, R., Jun 1 2019, In : Nature Medicine. 25, 6, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Glioblastoma
Immunotherapy
Medicine

Characterization of squamous cell lung cancers from Appalachian Kentucky

Liu, J., Murali, T., Yu, T., Liu, C., Sivakumaran, T. A., Moseley, H. N. B., Zhulin, I. B., Weiss, H. L., Durbin, E. B., Ellingson, S. R., Liu, J., Huang, B., Hallahan, B. J., Horbinski, C. M., Hodges, K., Napier, D. L., Bocklage, T., Mueller, J., Vanderford, N. L., Fardo, D. W. & 2 others, Wang, C. & Arnold, S. M., Feb 1 2019, In : Cancer Epidemiology Biomarkers and Prevention. 28, 2, p. 348-356 9 p.

Research output: Contribution to journalArticle

Squamous Cell Neoplasms
Lung Neoplasms
Squamous Cell Carcinoma
Atlases
Genome

Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

Zhai, L., Ladomersky, E., Lauing, K. L., Wu, M., Scholtens, D. M., Savoor, R., Zhang, B., Wu, J. D., Horbinski, C. M., Lukas, R. V., Binder, D. C. & Wainwright, D. A., Mar 4 2019, In : OncoImmunology. 8, 3, 1548242.

Research output: Contribution to journalComment/debate

Glioblastoma
Biomarkers
Computational Biology
Gene Expression
Open Access
Post Translational Protein Processing
Glioma
Histones
Immunohistochemistry
Pediatrics